Long Leukocyte Telomere Length at Diagnosis Is a Risk Factor for Dementia Progression in Idiopathic Parkinsonism
Open accessThe DOI matches its Crossref record; 2 of the 2 references it cites were found in a registry or an index.
Abstract
Telomere length (TL) is regarded as a marker of cellular aging due to the gradual shortening by each cell division, but is influenced by a number of factors including oxidative stress and inflammation. Parkinson's disease and atypical forms of parkinsonism occur mainly in the elderly, with oxidative stress and inflammation in afflicted cells. In this study the relationship between blood TL and prognosis of 168 patients with idiopathic parkinsonism (136 Parkinson's disease [PD], 17 Progressive Supranuclear Palsy [PSP], and 15 Multiple System Atrophy [MSA]) and 30 controls was investigated. TL and motor and cognitive performance were assessed at baseline (diagnosis) and repeatedly up to three to five years follow up. No difference in TL between controls and patients was shown at baseline, nor any significant difference in TL stability or attrition during follow up. Interestingly, a significant relationship between TL at diagnosis and cognitive phenotype at follow up in PD and PSP patients was found, with longer mean TL at diagnosis in patients that developed dementia within three years.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Litvan, I., Goldman, J. G., Tröster, A. I., Schmand, B. A., Weintraub, D., Petersen, R. C., Mollenhauer, B., Adler, C. H., Marder, K., Williams‐Gray, C. H., et al. (2012) · Movement Disorders · doi:10.1002/mds.24893 · Cited by 2,609
Hug, N., & Lingner, J. (2006) · Chromosoma · doi:10.1007/s00412-006-0067-3 · Cited by 291
Research works printed but not linked: 24
- L Kaszubowska, 2008, Telomere shortening and ageing of the immune system, J Physiol Pharmacol, 59, 169
- AH Schapira, 2011, Etiology and pathogenesis of Parkinson's disease, Mov Disord, 26, 1049, 10.1002/mds.23732 · DOI · Paper page
- Z Cai, 2013, Telomere shortening and Alzheimer's disease, Neuromolecular Med, 15, 25, 10.1007/s12017-012-8207-9 · DOI
- T Maeda, 2009, Aging-associated alteration of subtelomeric methylation in Parkinson's disease, J Gerontol A Biol Sci Med Sci, 64, 949, 10.1093/gerona/glp070 · DOI
- T Maeda, 2012, Aging-associated alteration of telomere length and subtelomeric status in female patients with Parkinson's disease, J Neurogenet, 26, 245, 10.3109/01677063.2011.651665 · DOI
- G Watfa, 2011, Study of telomere length and different markers of oxidative stress in patients with Parkinson's disease, J Nutr Health Aging, 15, 277, 10.1007/s12603-010-0275-7 · DOI
- J Eerola, 2010, No evidence for shorter leukocyte telomere length in Parkinson's disease patients, J Gerontol A Biol Sci Med Sci, 65, 1181, 10.1093/gerona/glq125 · DOI
- H Wang, 2008, Telomere length and risk of Parkinson's disease, Mov Disord, 23, 302, 10.1002/mds.21867 · DOI · Paper page
- M Schurks, 2014, Telomere length and Parkinson's disease in men: a nested case-control study, Eur J Neurol, 21, 93, 10.1111/ene.12252 · DOI
- G Hudson, 2011, No evidence of substantia nigra telomere shortening in Parkinson's disease, Neurobiol Aging, 32, e2103
- JL Sanders, 2013, Telomere Length in Epidemiology: A Biomarker of Aging, Age-Related Disease, Both, or Neither, Epidemiol Rev, 35, 112, 10.1093/epirev/mxs008 · DOI · Paper page
- WR Gibb, 1988, The relevance of the Lewy body to the pathogenesis of idiopathic Parkinson's disease, J Neurol Neurosurg Psychiatry, 51, 745, 10.1136/jnnp.51.6.745 · DOI · Paper page
- I Litvan, 1996, Clinical research criteria for the diagnosis of progressive supranuclear palsy (Steele-Richardson-Olszewski syndrome): report of the NINDS-SPSP international workshop, Neurology, 47, 1, 10.1212/WNL.47.1.1 · DOI · Paper page
- S Gilman, 1999, Consensus statement on the diagnosis of multiple system atrophy, J Neurol Sci, 163, 94, 10.1016/S0022-510X(98)00304-9 · DOI · Paper page
- CG Goetz, 2004, Movement Disorder Society Task Force report on the Hoehn and Yahr staging scale: status and recommendations, Mov Disord, 19, 1020, 10.1002/mds.20213 · DOI · Paper page
- M Emre, 2007, Clinical features, pathophysiology and treatment of dementia associated with Parkinson's disease, Handb Clin Neurol, 83, 401, 10.1016/S0072-9752(07)83018-1 · DOI
- RM Cawthon, 2002, Telomere measurement by quantitative PCR, Nucleic Acids Res, 30, e47, 10.1093/nar/30.10.e47 · DOI · Paper page
- JZ Guan, 2008, A percentage analysis of the telomere length in Parkinson's disease patients, J Gerontol A Biol Sci Med Sci, 63, 467, 10.1093/gerona/63.5.467 · DOI
- K Nordfjall, 2009, The individual blood cell telomere attrition rate is telomere length dependent, PLoS Genet, 5, e1000375, 10.1371/journal.pgen.1000375 · DOI · Paper page
- U Svenson, 2013, Telomere length in relation to immunological parameters in patients with renal cell carcinoma, PLoS One, 8, e55543, 10.1371/journal.pone.0055543 · DOI
- AD Reynolds, 2007, Neuroprotective activities of CD4+CD25+ regulatory T cells in an animal model of Parkinson's disease, J Leukoc Biol, 82, 1083, 10.1189/jlb.0507296 · DOI · Paper page
- D Rosenkranz, 2007, Higher frequency of regulatory T cells in the elderly and increased suppressive activity in neurodegeneration, J Neuroimmunol, 188, 117, 10.1016/j.jneuroim.2007.05.011 · DOI · Paper page
- JA Saunders, 2012, CD4+ regulatory and effector/memory T cell subsets profile motor dysfunction in Parkinson's disease, J Neuroimmune Pharmacol, 7, 927, 10.1007/s11481-012-9402-z · DOI · Paper page
- HJ Lee, 2014, Extracellular alpha—synuclein-a novel and crucial factor in Lewy body diseases, Nat Rev Neurol, 10, 92, 10.1038/nrneurol.2013.275 · DOI · Paper page
Cited by
Ageing, Cellular Senescence and Neurodegenerative Disease
Kritsilis, M., V. Rizou, S., Koutsoudaki, P. N., Evangelou, K., Gorgoulis, V. G., & Papadopoulos, D. (2018) · International Journal of Molecular Sciences · doi:10.3390/ijms19102937 · Cited by 448
Cellular Senescence in Neurodegenerative Diseases
Martínez-Cué, C., & Rueda, N. (2020) · Frontiers in Cellular Neuroscience · doi:10.3389/fncel.2020.00016 · Cited by 281
Cellular senescence in the aging brain: A promising target for neurodegenerative diseases
Sahu, M. R., Rani, L., Subba, R., & Mondal, A. C. (2022) · Mechanisms of Ageing and Development · doi:10.1016/j.mad.2022.111675 · Cited by 75
Telomere length in Parkinson's disease: A meta-analysis
Forero, D. A., González-Giraldo, Y., López-Quintero, C., Castro-Vega, L. J., Barreto, G. E., & Perry, G. (2016) · Experimental Gerontology · doi:10.1016/j.exger.2016.01.002 · Cited by 70
“Eight primary studies were included in the meta-analysis for PD and telomere length (Degerman et al., 2014; Eerola et al., 2010; Guan et al., 2008; Hudson et al., 2011; Schurks et al., 2014; Wang et al., 2008; Watfa et al., 2011).”
BackgroundInfluentialAge-Related Adaptive Immune Changes in Parkinson’s Disease
Kouli, A., & Williams-Gray, C. H. (2022) · Journal of Parkinson's Disease · doi:10.3233/jpd-223228 · Cited by 20
Metadata
- Authors
- Degerman, S., Domellöf, M., Landfors, M., Linder, J., Lundin, M., Haraldsson, S., Elgh, E., Roos, G., & Forsgren, L.
- Venue
- PLoS ONE
- Publisher
- Public Library of Science (PLoS)
- Published
- 2014-12-12
- Volume
- 9
- Issue
- 12
- Pages
- e113387
- ISSN
- 1932-6203 (ISSN-L)
- OpenAlex
- W2079744861
- Cited by
- 32
- References
- 2
- FWCI
- 1.16
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Long Leukocyte Telomere Length at Diagnosis Is a Risk Factor for Dementia Progression in Idiopathic Parkinsonism. https://app.cochat.ai/papers/10.1371/journal.pone.0113387
- The paper
- Degerman, S., Domellöf, M., Landfors, M., Linder, J., Lundin, M., Haraldsson, S., Elgh, E., Roos, G., & Forsgren, L. (2014). Long Leukocyte Telomere Length at Diagnosis Is a Risk Factor for Dementia Progression in Idiopathic Parkinsonism. PLoS ONE. https://doi.org/10.1371/journal.pone.0113387
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.